| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |